GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Biochimica et Biophysica Acta

• Publication date

  2011-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.bbadis.2011.03.018PMID 21497194PMCID PMC3210552
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial.

  2010cited by this paper
• Substrate reduction therapy with miglustat in chronic GM2 gangliosidosis type Sandhoff: results of a 3-year follow-up

  2010cited by this paper
• Clinical experience with miglustat therapy in pediatric patients with Niemann-Pick disease type C: a case series.

  2010cited by this paper
• Phenotype determining alleles in GM1 gangliosidosis patients bearing novel GLB1 mutations

  2010cited by this paper
• Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project

  2009cited by this paper
• Structural bases of GM1 gangliosidosis and Morquio B disease

  2009cited by this paper
• New GLB1 mutation in siblings with Morquio type B disease presenting with mental regression.

  2009cited by this paper
• MR Imaging Findings in 2 Cases of Late Infantile GM1 Gangliosidosis

  2009cited by this paper
• The potential action of galactose as a "chemical chaperone": increase of beta galactosidase activity in fibroblasts from an adult GM1-gangliosidosis patient.

  2009cited by this paper
• Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis.

  2008cited by this paper
• GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects.

  2008cited by this paper
• Identification of 14 novel GLB1 mutations, including five deletions, in 19 patients with GM1 gangliosidosis from South America

  2007cited by this paper
• Trp/Met/Phe hot spots in protein-protein interactions: potential targets in drug design.

  2007cited by this paper
• GM1 gangliosidosis: molecular analysis of nine patients and development of an RT‐PCR assay for GLB1 gene expression profiling

  2007cited by this paper
• Expression and characterization of 14 GLB1 mutant alleles found in GM1-gangliosidosis and Morquio B patients Published, JLR Papers in Press, July 30, 2007.

  2007cited by this paper
• Twenty‐one novel mutations in the GLB1 gene identified in a large group of GM1‐gangliosidosis and Morquio B patients: possible common origin for the prevalent p.R59H mutation among gypsies

  2006cited by this paper
• Dystonia and parkinsonism in GM1 type 3 gangliosidosis

  2005cited by this paper
• Primary and secondary elastin-binding protein defect leads to impaired elastogenesis in fibroblasts from GM1-gangliosidosis patients.

  2005cited by this paper
• Clinical features of adult GM1 gangliosidosis: Report of three Indian patients and review of 40 cases

  2004cited by this paper
• Modulating action of the new polymorphism L436F detected in the GLB1 gene of a type-II GM1 gangliosidosis patient

  2003cited by this paper
• Incidence of the mucopolysaccharidoses in Western Australia

  2003cited by this paper
• Novel mutations (Asn 484 Lys, Thr 500 Ala, Gly 438 Glu) in Morquio B disease.

  2002influential reference
• Signaling Pathways Transduced through the Elastin Receptor Facilitate Proliferation of Arterial Smooth Muscle Cells*

  2002cited by this paper
• Corrigendum: Mutation nomenclature extensions and suggestions to describe complex mutations: A discussion

  2002cited by this paper
• Lysosomal multienzyme complex: biochemistry, genetics, and molecular pathophysiology.

  2001cited by this paper
• Residue frequencies and pairing preferences at protein–protein interfaces

  2001cited by this paper
• Mutation analyses in 17 patients with deficiency in acid β-galactosidase: three novel point mutations and high correlation of mutation W273L with Morquio disease type B

  2001cited by this paper
• The Metabolic and Molecular Bases of Inherited Disease

  2001cited by this paper
• Processing of Lysosomal β-Galactosidase

  2000cited by this paper
• Characterization of beta-galactosidase mutations Asp332-->Asn and Arg148-->Ser, and a polymorphism, Ser532-->Gly, in a case of GM1 gangliosidosis.

  2000influential reference
• β‐galactosidase gene mutations affecting the lysosomal enzyme and the elastin‐binding protein in GM1‐gangliosidosis patients with cardiac involvement

  2000cited by this paper
• Processing of lysosomal beta-galactosidase. The C-terminal precursor fragment is an essential domain of the mature enzyme.

  2000cited by this paper
• Impaired elastic-fiber assembly by fibroblasts from patients with either Morquio B disease or infantile GM1-gangliosidosis is linked to deficiency in the 67-kD spliced variant of beta-galactosidase.

  2000cited by this paper
• Mutation nomenclature extensions and suggestions to describe complex mutations: A discussion

  2000cited by this paper
• The atomic structure of protein-protein recognition sites.

  1999cited by this paper
• Six novel β‐galactosidase gene mutations in Brazilian patients with GM1‐gangliosidosis

  1999cited by this paper
• Molecular basis of GM1 gangliosidosis and Morquio disease, type B. Structure-function studies of lysosomal beta-galactosidase and the non-lysosomal beta-galactosidase-like protein.

  1999cited by this paper
• The 67-kDa Enzymatically Inactive Alternatively Spliced Variant of β-Galactosidase Is Identical to the Elastin/Laminin-binding Protein*

  1998cited by this paper
• Identification of Glu-268 as the Catalytic Nucleophile of Human Lysosomal β-Galactosidase Precursor by Mass Spectrometry*

  1997cited by this paper
• Incidence of the mucopolysaccharidoses in Northern Ireland

  1997cited by this paper
• β-Galactosidase Gene Mutations in Patients With Slowly Progressive GM1 Gangliosidosis

  1997cited by this paper
• Biological roles of the non-integrin elastin/laminin receptor.

  1996cited by this paper
• 67-kD elastin-binding protein is a protective "companion" of extracellular insoluble elastin and intracellular tropoelastin

  1994cited by this paper
• Mutations in the lysosomal beta-galactosidase gene that cause the adult form of GM1 gangliosidosis.

  1994cited by this paper
• Mutations in acid beta-galactosidase cause GM1-gangliosidosis in American patients.

  1993cited by this paper
• Human beta-galactosidase gene mutations in morquio B disease.

  1991cited by this paper

• From Molecule to Meaning: Neuronopathic Biomarkers and Clinical Relevance in GM1

  2026cites this paper
• Clinical, Radiological, and Genetic Profiles of Eight Patients with Combined Dystonic Manifestation of Type-III GM1 Gangliosidosis: A Video Case Series from India

  2026cites this paper
• Targeted proteomics reveals immune protein patterns in serum from patients with calcific aortic stenosis

  2025cites this paper
• Synthesis of an N‐Galactosyl Norbornane Aziridine and its Potent Mixed Inhibition of Aspergillus oryzae β‐Galactosidase

  2025cites this paper
• Mucopolysaccharidoses—What Clinicians Need to Know: A Clinical, Biochemical, and Molecular Overview

  2025cites this paper
• The Critical Role of Vitamin D Supplementation for Skeletal and Neurodevelopmental Outcomes in Preterm Neonates

  2025cites this paper
• Sphingolipidoses and Retinal Involvement: A Comprehensive Review

  2025cites this paper
• Editorial: Role of neuroimaging in the diagnosis and treatment of rare diseases

  2025cites this paper
• GM1 - gangliosidosis, type 1 in the practice of a clinical laboratory diagnostics doctor

  2025cites this paper
• Persistent elevations of alkaline phosphatase as an early indicator of GM1 gangliosidosis

  2025cites this paper
• Clinical and genetic analysis of a Chinese family with GM1 gangliosidosis caused by a novel mutation in GLB1 gene

  2025cites this paper
• Mapping Lysosomal Storage Disorders with Neurological Features by Cellular Pathways: Towards Precision Medicine

  2025cites this paper
• GM1 Gangliosidosis Type II: Results of a 10-Year Prospective Study.

  2024cites this paper
• GM1 Gangliosidosis Type II: Results of a 10-Year Prospective Study

  2024cites this paper
• Generation of an infantile GM1 gangliosidosis induced pluripotent stem cell line (CHOCi005-A) for disease modeling and therapeutic testing.

  2024cites this paper
• Base editing of the GLB1 gene is therapeutic in GM1 gangliosidosis patient-derived cells.

  2024cites this paper
• Lung Diseases and Rare Disorders: Is It a Lysosomal Storage Disease? Differential Diagnosis, Pathogenetic Mechanisms and Management

  2024cites this paper
• Causes of death in mucopolysaccharidoses.

  2024cites this paper
• Congenital Heart Malformations Masked by Infantile Gangliosidosis—Case Report and Growing Evidence for Metabolic Disease-Associated Aortopathies

  2024cites this paper
• A clinical case of ischemic stroke in a young patient with a previously undescribed nucleotide sequence c.808T > C (p.Tyr270His of the GLBI gene (NM_ 000404.3, GMI-gangliosidosis type 2) in a heterozygous state

  2023cites this paper
• GM1 gangliosidosis: patients with different phenotypic features and novel mutations

  2023cites this paper
• Gene therapy approaches for GM1 gangliosidosis: Focus on animal and cellular studies

  2023cites this paper
• GM1 Gangliosidosis Revealed by Fetoplacental Hydrops Syndrome: A Case Report

  2023cites this paper
• A Case of GM 1 Gangliosidosis Type 2 Mimicking Zellweger Syndrome

  2023cites this paper
• From amaurotic idiocy to biochemically defined lipid storage diseases: the first identification of GM1-Gangliosidosis.

  2023cites this paper
• Experimental pharmacology: Targeting metabolic pathways.

  2023cites this paper
• Natural history of GM1 gangliosidosis—Retrospective cohort study of 61 French patients from 1998 to 2019

  2023cites this paper
• Rare Diseases in Glycosphingolipid Metabolism.

  2022cites this paper
• Emerging Perspectives on Gene Therapy Delivery for Neurodegenerative and Neuromuscular Disorders

  2022cites this paper
• Mitochondria-associated niches in health and disease.

  2022cites this paper
• β‐Galactosidase deficiency in the GLB1 spectrum of lysosomal storage disease can present with severe muscle weakness and atrophy

  2022influential citation
• Fluorescent In Situ Staining and Flow Cytometric Procedures as New Pre-Diagnostic Tests for Sialidosis, GM1 Gangliosidosis and Niemann–Pick Type C

  2022cites this paper
• Establishment of blood glycosidase activities and their excursions in sepsis

  2022cites this paper
• Synthesis of a New β-Galactosidase Inhibitor Displaying Pharmacological Chaperone Properties for GM1 Gangliosidosis

  2022cites this paper
• Abnormal DaTscan in GM1‐Gangliosidosis Type III Manifesting with Dystonia‐Parkinsonism

  2022cites this paper
• Morquio B disease: From pathophysiology towards diagnosis.

  2021cites this paper
• TACG_A_206076 209..233

  2021influential citation
• A computational approach to analyse the amino acid variants of GLB1 protein causing GM1 Gangliosidosis

  2021cites this paper
• Clinical and Radiological Characterisation of Patients with Mucopolysaccharidosis in a Genetic Clinic

  2021cites this paper
• GM1 Gangliosidosis—A Mini-Review

  2021cites this paper
• A 7‐month‐old boy with failure to thrive

  2021cites this paper
• A pathogenic HEXA missense variant in wild boars with Tay-Sachs disease.

  2021cites this paper
• Are GMI gangliosidosis and Morquio type B two different disorders or part of one phenotypic spectrum?

  2021influential citation
• Sphingolipid lysosomal storage diseases: from bench to bedside

  2021cites this paper
• GM1 Gangliosidosis: Mechanisms and Management

  2021influential citation
• Rapid Identification of New Biomarkers for the Classification of GM1 Type 2 Gangliosidosis Using an Unbiased 1H NMR-Linked Metabolomics Strategy

  2021cites this paper
• Disentangling molecular and clinical stratification patterns in beta-galactosidase deficiency

  2021cites this paper
• Coarse face, hypotonia, and neurodevelopmental regression

  2020cites this paper
• Transcriptomic Changes Related to Cellular Processes with Particular Emphasis on Cell Activation in Lysosomal Storage Diseases from the Group of Mucopolysaccharidoses

  2020influential citation
• An autopsy case of GM1 gangliosidosis type II in a patient who survived a long duration with artificial respiratory support

  2020cites this paper
• Axonopathy and Reduction of Membrane Resistance: Key Features in a New Murine Model of Human GM1-Gangliosidosis

  2020cites this paper
• Rapamycin promotes endothelial–mesenchymal transition during stress-induced premature senescence through the activation of autophagy

  2020cites this paper
• The mucopolysaccharidoses

  2020cites this paper
• β-Galactosidase deficiency: GM1 gangliosidosis, Morquio B disease, and galactosialidosis

  2020cites this paper
• Oligosaccharidosen und verwandte Krankheiten

  2020cites this paper
• Manifestaciones osteoarticulares de las esfingolipidosis en adultos

  2020cites this paper
• Estimated prevalence of mucopolysaccharidoses from population-based exomes and genomes

  2020cites this paper
• Synthesis of “All-Cis” Trihydroxypiperidines from a Carbohydrate-Derived Ketone: Hints for the Design of New β-Gal and GCase Inhibitors

  2020cites this paper
• Manifestations ostéoarticulaires des sphingolipidoses de l’adulte

  2020cites this paper
• Metabolism of Glycosphingolipids and Their Role in the Pathophysiology of Lysosomal Storage Disorders

  2020cites this paper
• The pharmacological chaperone N-n-butyl-deoxygalactonojirimycin enhances β-galactosidase processing and activity in fibroblasts of a patient with infantile GM1-gangliosidosis

  2020cites this paper
• Genetic Assessment of Mucopolysaccharidosis Type IV and the First Pathological Mutation of c.313A>G in the Iranian Population

  2020cites this paper
• Type I sialidosis, a normosomatic lysosomal disease, in the differential diagnosis of late-onset ataxia and myoclonus: An overview.

  2019cites this paper
• Infantile GM1-Gangliosidosis Revealed by Slate-Grey Mongolian Spots

  2019cites this paper
• Lysosomal Glycosphingolipid Storage Diseases.

  2019cites this paper
• Genotype-phenotype correlation of gangliosidosis mutations using in silico tools and homology modeling

  2019cites this paper
• Clinical findings in Brazilian patients with adult GM1 gangliosidosis

  2019cites this paper
• Intracerebroventricular enzyme replacement therapy with β-galactosidase reverses brain pathologies due to GM1 gangliosidosis in mice

  2019cites this paper
• Human GLB1 knockout cerebral organoids: A model system for testing AAV9-mediated GLB1 gene therapy for reducing GM1 ganglioside storage in GM1 gangliosidosis

  2019cites this paper
• The Clinical and Molecular Spectrum of GM1 Gangliosidosis.

  2019cites this paper
• Pre-diagnosing and managing patients with GM1 gangliosidosis and related disorders by the evaluation of GM1 ganglioside content

  2019cites this paper
• Advances in Sphingolipidoses: CRISPR-Cas9 Editing as an Option for Modelling and Therapy

  2019cites this paper
• Progressive dystonia as a presenting manifestation of GM1 gangliosidosis

  2019cites this paper
• The natural history of Type 1 infantile GM1 gangliosidosis: A literature-based meta-analysis.

  2019cites this paper
• Neuroimaging Findings in Lysosomal Disorders: 2018 Update

  2018cites this paper
• Diagnostic challenge for the rare lysosomal storage disease: Late infantile GM1 gangliosidosis.

  2018cites this paper
• Evaluating hydrophobic galactonoamidines as transition state analogs for enzymatic β-galactoside hydrolysis.

  2018cites this paper
• SAAMP 2.0: An algorithm to predict genotype‐phenotype correlation of lysosomal storage diseases

  2018cites this paper
• Mosaic uniparental disomy results in GM1 gangliosidosis with normal enzyme assay

  2018influential citation
• Ganglioside Metabolism in Health and Disease.

  2018cites this paper
• Congenital Disorders of Ganglioside Biosynthesis.

  2018cites this paper
• Molecular genetics and metabolism, special edition: Diagnosis, diagnosis and prognosis of Mucopolysaccharidosis IVA.

  2018cites this paper
• Disorders of Carbohydrate Metabolism

  2018cites this paper
• Genetic Analysis of Undiagnosed Juvenile GM1-Gangliosidosis by Microarray and Exome Sequencing

  2018cites this paper
• Mucopolysaccharidoses: early diagnostic signs in infants and children

  2018cites this paper
• Biochemical and molecular analysis in mucopolysaccharidoses: what a paediatrician must know

  2018cites this paper
• Mis-splicing of the GALNS gene resulting from deep intronic mutations as a cause of Morquio a disease

  2018cites this paper
• Identification of a novel GLB1 mutation in a consanguineous Pakistani family affected by rare infantile GM1 gangliosidosis

  2018cites this paper
• 4-epi-Isofagomine derivatives as pharmacological chaperones for the treatment of lysosomal diseases linked to β-galactosidase mutations: Improved synthesis and biological investigations.

  2018cites this paper
• Clinical and molecular characteristics of 11 Chinese probands with GM1 gangliosidosis

  2018cites this paper
• Protein modeling and clinical description of a novel in‐frame GLB1 deletion causing GM1 gangliosidosis type II

  2018cites this paper
• Identification of a novel GLB1 mutation in a consanguineous Pakistani family affected by rare infantile GM1 gangliosidosis

  2018cites this paper
• Mucopolisacaridosis y oligosacaridosis: manifestaciones osteoarticulares

  2017cites this paper
• Age-related modulation of plasmatic beta-Galactosidase activity in healthy subjects and in patients affected by T2DM

  2017cites this paper
• (5aR)-5a-C-Pentyl-4-epi-isofagomine: A powerful inhibitor of lysosomal β-galactosidase and a remarkable chaperone for mutations associated with GM1-gangliosidosis and Morquio disease type B.

  2017cites this paper
• Major mutation p.His281Tyr in Gene GLB1 in patients with GM1-gangliosidosis in Ukraine

  2017cites this paper
• The treatment of juvenile/adult GM1-gangliosidosis with Miglustat may reverse disease progression

  2017cites this paper
• Mucopolysaccharidoses et oligosaccharidoses : manifestations ostéoarticulaires

  2017cites this paper
• Catabolism of N-glycoproteins in mammalian cells: Molecular mechanisms and genetic disorders related to the processes.

  2016cites this paper
• Improving the cellular immunogenicity of recombinant Modified Vaccinia virus Ankara using green fluorescent protein as model system

  2016cites this paper